12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

REGN910: Phase Ib started

Regeneron disclosed in its 3Q12 earnings that in September it began an open-label Phase Ib trial to evaluate multiple ascending-doses of REGN910 plus Zaltrap ziv-aflibercept in about 40 patients with advanced solid...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >